<p>，/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者注意针对 Replimune Group, Inc.（&#34;Replimune&#34;或&#34;公司&#34;）（NASDAQ: REPL）的集体诉讼，该诉讼因违反 1934 年证券交易法第 10(b) 条和第 20(a) 条以及美国证券交易委员会制定的第 10b-5 条而提起。</p>
<p>在 2024 年 11 月 22 日至 2025 年 7 月 21 日期间（&#34;集体诉讼期间&#34;）购买了公司证券的投资者，鼓励在 2025 年 9 月 22 日之前与本事务所联系。</p>
<p>如果您是遭受损失的股东，请点击这里参与。</p>
<p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
<p>本案的集体诉讼尚未获得认证，在认证之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
<p>根据投诉，公司向市场发布了虚假和误导性陈述。Replimune 夸大了其针对 RP1（vusolimogene oderparepvec）的 IGNYTE 试验的前景。公司知道或应该知道该试验存在重大问题，这将导致 FDA 认为该试验不充分且控制不当。基于这些事实，公司在集体诉讼期间的公开声明是虚假且具有重大误导性的。当市场了解到 Replimune 的真相时，投资者遭受了损失。</p>
<p>加入本案以追回您的损失。</p>
<p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
<p>本新闻稿在某些司法管辖区可能被视为律师广告，依据适用法律和伦理规则。</p>
<p><strong>联系方式：</strong></p>
<p>Schall 律师事务所</p>
<p>Brian Schall, Esq.,</p>
<p>www.schallfirm.com</p>
<p>办公室：310-301-3335</p>
<p>[email protected]</p>
<p>来源：Schall 律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ1UFJfTkVXU19VU1BSX19fX19MQTM4NDA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ1UFJfTkVXU19VU1BSX19fX19MQTM4NDA0"/></p>

REPL

<p>Schall 律师事务所提醒投资者，针对 Replimune Group, Inc.的证券欺诈违规行为提起了集体诉讼。购买了 Replimune 证券的投资者，时间在 2024 年 11 月 22 日至 2025 年 7 月 21 日之间，鼓励在 2025 年 9 月 22 日之前与该事务所联系。诉讼声称 Replimune 在其 RP1 的 IGNYTE 试验中做出了虚假陈述，当真相被揭露时导致投资者损失。该事务所专注于证券集体诉讼，并为受影响的股东提供免费的咨询服务</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (&#34;Replimune&#34; or &#34;the Company&#34;) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者注意针对 Replimune Group, Inc.（&#34;Replimune&#34;或&#34;公司&#34;）（NASDAQ: REPL）的集体诉讼，该诉讼因违反 1934 年证券交易法第 10(b) 条和第 20(a) 条以及美国证券交易委员会制定的第 10b-5 条而提起。</p>
</div><p>Investors who purchased the Company's securities between November 22, 2024 and July 21, 2025, inclusive (the &#34;Class Period&#34;), are encouraged to contact the firm before September 22, 2025.</p>
<div class="lb-trans"><p>在 2024 年 11 月 22 日至 2025 年 7 月 21 日期间（&#34;集体诉讼期间&#34;）购买了公司证券的投资者，鼓励在 2025 年 9 月 22 日之前与本事务所联系。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受损失的股东，请点击这里参与。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
</div><p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
<div class="lb-trans"><p>本案的集体诉讼尚未获得认证，在认证之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
</div><p>According to the Complaint, the Company made false and misleading statements to the market. Replimune overstated the prospects of its IGNYTE trial for RP1 (vusolimogene oderparepvec). The Company knew or should have known of material issues with the trial that would result in the FDA finding it was inadequate and poorly controlled. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.</p>
<div class="lb-trans"><p>根据投诉，公司向市场发布了虚假和误导性陈述。Replimune 夸大了其针对 RP1（vusolimogene oderparepvec）的 IGNYTE 试验的前景。公司知道或应该知道该试验存在重大问题，这将导致 FDA 认为该试验不充分且控制不当。基于这些事实，公司在集体诉讼期间的公开声明是虚假且具有重大误导性的。当市场了解到 Replimune 的真相时，投资者遭受了损失。</p>
</div><p>Join the case to recover your losses.</p>
<div class="lb-trans"><p>加入本案以追回您的损失。</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>本新闻稿在某些司法管辖区可能被视为律师广告，依据适用法律和伦理规则。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律师事务所</p>
</div><p>Brian Schall, Esq.,</p>
<div class="lb-trans"><p>Brian Schall, Esq.,</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>Office: 310-301-3335</p>
<div class="lb-trans"><p>办公室：310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>来源：Schall 律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ1UFJfTkVXU19VU1BSX19fX19MQTM4NDA0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA38404&amp;Transmission_Id=202507281045PR_NEWS_USPR_____LA38404&amp;DateId=20250728"/></p>

REPL 投资者有机会与 Schall 律师事务所合作，主导 Replimune Group, Inc.的证券欺诈诉讼